LDN for Treating Spike Protein Injuries, Diseases

LDN for Treating Spike Protein Injuries, Diseases
Yuhong Dong

Claudia Ann Christian, a greatly successful American actress, suffered from alcohol addiction for over a decade. She felt that something else was controlling her, as if she was not in the “driver’s seat.”

She spent a fortune trying to find a cure in vain. Then she discovered Naltrexone and was able to overcome her alcoholism after using a single dose.

In 1984, the FDA approved 50 milligrams of Naltrexone as a treatment for heroin addiction.

Later, people discovered that low-dose naltrexone (LDN) can also be used to treat other illnesses.

Due to the pandemic, long COVID and COVID vaccine-related syndromes have become a major health concern in society.

In addition to Ivermectin, research has discovered that low-dose naltrexone might be a good treatment for long COVID and vaccine injuries.

How could this be? Let’s take a closer look at the complete history of low-dose naltrexone.

Low-Dose Naltrexone (LDN) Might Treat Cancer

Scientists have found that aside from its original application in treating drug addiction, naltrexone, in small doses, can be used for treating four other common diseases.

1. Treating Tumors

In 1983, Dr. Ian Zagon and Dr. Patricia McLaughlin of Penn State Hershey Medical Center co-authored a paper in Science that first described the significant inhibitory effect of LDN on the growth of neuroblastoma in mice.

The experiments were conducted by subcutaneously injecting naltrexone at 0.1, 1, or 10 mg/kg body weight per day into mice inoculated with neuroblastoma.

The naltrexone low-dose group of 0.1 mg/kg (hollow circles) showed a 36 percent increase in survival time compared to the control group injected with distilled water (x). The naltrexone high-dose group of 10 mg/kg body weight (solid squares) showed a 19 percent decrease in survival.

In addition, there was a 98 percent delay in time to tumor onset in the low-dose naltrexone group.

The data from this experiment suggests that LDN has an inhibitory effect on cancer. The main effect of LDN is through activation of the endogenous opioid receptor system and promoting the release of endorphins.

The most important function of endorphins is to enhance immunity so that a greater number of immune cells are released and the overall immune function is improved, enabling cancer cells to be killed by the internal immune system.

2. Treating HIV/AIDS

Dr. Bernard Bihari, a Harvard graduate, and New York physician, began searching for ways to help restore the immune system of people with AIDS after seeing the 1985 epidemic in the United States.

In 1986, his clinical trial at Downstate Medical Center showed that LDN protected AIDS patients by repairing their compromised immune systems.

Approximately 31 percent of patients in the control group, who received a placebo, developed contagious infections during the trial.
In contrast, none of the 22 patients in the experimental group receiving LDN developed any contagious infections.

3. Treating Multiple Sclerosis

In 2008, LDN was first used spontaneously (without external intervention) by multiple sclerosis (MS) patients worldwide, with promising results before medical institutions conducted rigorous clinical trials.

It was found that LDN can not only prevent the recurrence of MS but also reduce the progression of the disease.

A series of trials in MS patients with multiple types including relapsing-remitting, secondary progressive, and primary progressive have shown that LDN is well tolerated while significantly improving the patient's quality of life and mental health.

The data suggest that LDN is a safe, non-toxic, and inexpensive biotherapeutic for MS.

For example, a single-center, double-blind, placebo-controlled, crossover study evaluated the efficacy of eight weeks of LDN 4.5 milligrams on the self-reported quality of life of MS patients.

Eighty subjects were enrolled, and 60 subjects completed the trial.

LDN treatment was associated with a significant improvement in the following symptoms:
  • A 3.3-point improvement on the mental score of Short Form-36 General Health Survey and a 6-point improvement on the Mental Health Inventory.
  • A 1.6-point improvement on the Pain Scale, and a 2.4-point improvement on the Perceived Deficits Questionnaire.

4. Treating Irritable Bowel Syndrome

An Israeli study involving 42 patients with irritable bowel syndrome (IBS) was first conducted in 2006.

It was an open-label study that lasted for four weeks and the patients were given 0.5 milligrams of LDN daily.

Subjective measures of pain-free days and symptom relief occurred in over 75 percent of the patients. The drug was also well tolerated.

LDN May Improve Long COVID Symptoms

A study was conducted with 52 COVID-19 patients whose median age was 43.5. Forty patients were female. Healthcare workers amounted to 34.8 percent.

The median time from diagnosis of COVID-19 to enrollment was 333 days. Thirty-eight enrollees (73.1 percent) started LDN.

At the end of two months of follow-up, 36 participants(69.2 percent) had completed the survey.

Six of the seven parameters measured had improved, including a significant recovery from long COVID-induced discomforts of daily activities, energy, pain, attention, and sleep disturbances.

There was also a slight improvement in mood.

The occurrence rate of specific symptoms, including depressed mood, personality changes, brain fog, and joint pain, was also significantly improved.

LDN Helps Fibromyalgia Symptoms

One study found that 30 percent of people who have long COVID suffer from fibromyalgia.

Fibromyalgia is a state of increased microglial cell activity and inflammation in the central nervous system. Once activated, these cells produce pro-inflammatory factors that lead to symptoms such as pain hypersensitivity and fatigue.

LDN is reported to lessen fibromyalgia symptoms.

In an eight-week single-blind, crossover design pilot study of baseline (two weeks), placebo (two weeks), drug (eight weeks), and clearance (two weeks), fibromyalgia symptoms were reduced by more than 30 percent with 4.5 milligrams LDN per night compared to use of placebo.

In addition, the drug improved mechanical and thermal pain thresholds.

Side effects (including insomnia and vivid dreams) were rare and were described as mild.

Multiple pro-inflammatory cytokines, including interleukins, were significantly reduced in patients with fibromyalgia.

LDN Helps Chronic Fatigue Syndrome

Chronic fatigue syndrome is also a common problem with long COVID.
In January 2020, the British Medical Journal published three reports of positive therapeutic effects of LDN on chronic fatigue associated with Epstein-Barr virus (EBV), from life-changing to a reduction in some symptoms. The therapeutic dose range is 4 to 12 milligrams.

How Does LDN Work?

Naltrexone is initially used to treat withdrawal symptoms of opioid and alcohol addiction at doses ranging from 50-200 milligrams/day, as this level of dose completely blocks both endogenous opioids (endorphins, the natural "happy hormones") and exogenous opioids (such as heroin).

Low doses range from 0.5 to 4.5 milligrams/day, equaling 1/10 to 1/100 of the normal dose.

Every drug has two structures called isomers that mirror each other (levorotatory and dextrorotatory), just like the left and right hand of a person. Usually, only one isomer provides a therapeutic effect.

Naltrexone is unique in that both isomers have different therapeutic effects.

LDN Stimulates Endorphin Production

Studies have shown that LDN acts on opioid receptors, increasing the level of endogenous opioids and stimulating the production of endorphins.

A 2008 study found that endorphins kept increasing even one month after stopping a dose of less than 5.0 milligrams of LDN.

Ninety percent of endorphins are actually secreted between 2 a.m. and 4 a.m., so we should sleep early and avoid staying up all night.

LDN Modulates the OGFr Axis Pathway

Opioid receptors exist in the human body in various subtypes: μ, κ, δ, σ, etc.

One of these subtypes is also known as the Opioid Growth Factor (OGF) receptor, and the OGF/OGF receptor axis pathway is involved in the regulation of tumor growth and proliferation.

When OGF binds to the OGF receptor, cell proliferation will be altered.

Tumor growth is inhibited when the OGF/OGFr axis pathway is upregulated. Low doses of naltrexone upregulate the OGF/OGFr axis and therefore inhibit tumor growth and treat tumors.

In addition, it can also treat autoimmune diseases. These include multiple sclerosis, Crohn's disease, diabetes, and cancer, as well as mental disorders, all of which are associated with dysfunction of the OGF/OGFr axis.

Therefore, naltrexone has the potential to be used to treat a variety of diseases.

LDN Decreases Pro-inflammatory Cytokines, Increases Anti-Inflammatory Factors

A balanced immune system depends on the body's ability to balance pro-inflammatory and anti-inflammatory factors.

Through multiple means, LDN can decrease pro-inflammatory cytokines, thus reducing inflammation.

A class of proteins called toll-like receptors (TLRs) is part of the immune system. It provides the first line of defense against microbial invasion and has the ability to recognize and activate pathogens and endogenous signaling molecules.

LDN can reduce toll-like receptor-4 signaling and subsequently induces neuroinflammation, as well as potentially re-balance the dysregulated Th1 and Th2 cytokine immune responses in COVID conditions.

Th1 cytokines tend to respond to viral bacteria. Interferon γ is the main Th1 cytokine. Th2 cytokines including interleukins 4, 5, and 13, are associated with the triggering of allergic and eosinophilic responses.

Therefore, LDN can be helpful in reducing long COVID symptoms.

LDN and Spike Protein Injuries

At least two-thirds of the world's population has received COVID-19 vaccines, in which spike protein is the main ingredient.

There have been at least 1,200 scientific studies on the cellular, tissue, and organ-level damages brought about by spike proteins.

The most important pathological mechanisms are the following:

Spike protein induces inflammatory responses and activates the monocytes in almost every organ of the body.

Most notably, it involves the brain (brain fog, dementia, mood disorders, psychiatric abnormalities), heart, and endocrine system. These can be life-threatening.

Spike proteins can decrease NK cells and inhibit their activity, and reactivate latent viruses, further inhibiting the immune system, thus creating a vicious cycle.
Other issues include damage caused by microvascular injury, mitochondrial dysfunction, autoimmune diseases, etc.

Theoretically speaking, LDN can alleviate systemic inflammatory and neuroinflammatory diseases by inhibiting various inflammatory factors and reducing the body’s reaction to inflammations.

LDN inhibits the activation of microglia in the nervous system and reduces the toxic effects of reactive oxygen species and other potentially neuroexcitatory and neurotoxic chemical production. Thus, it can protect the brain and nerve cells.

Based on previous dosing experience, patients could theoretically start with a small dose, slowly increasing it—starting with doses of 0.5 to 1.5 milligrams per day up to a maximum dose of 4.5 milligrams.

LDN’s Multiple Treatment Potential Brings Hope

Once the body's natural self-regulatory mechanisms are disrupted by external drugs, viruses, and toxins, disorders may occur, such as addiction, COVID-19, or COVID vaccine injury.

In addition to forcibly blocking external stimuli (for example, the addictive drugs), the most fundamental treatment requires the body's natural mechanisms to return to normal.

The idea of medical treatment is mainly to suppress symptoms, it is a reactive action but not a proactive measurement.  This approach equates one disease to one target, and pairs it with one drug.

The fact that low-dose naltrexone, a drug originally used to treat drug addiction can actually treat other chronic illnesses suggests that the human body is a complex, multidimensional system that to date is still poorly understood.

Little is known about the interconnectedness of the brain, the immune system, and the various organs of the body.

Yet, many traditional therapies or natural therapies are able to heal the whole body at a deeper, microscopic level.

The subtleties of the human body still need to be explored with open-mindedness, so as to better understand it. Only when we are able to do this in a humble way will we be able to find a holistic way to achieve ultimate health.

Dr. Yuhong Dong is a senior medical columnist for The Epoch Times. She is a former senior medical scientific expert and pharmacovigilance leader at the Novartis headquarters in Switzerland and a four-time Novartis award winner. She has preclinical research experience in virology, immunology, oncology, neurology, and ophthalmology, and also has clinical experience in infectious disease and internal medicine. She earned her MD and a doctorate in infectious diseases at Beijing University in China.